Werewolf Therapeutics (HOWL)
(Delayed Data from NSDQ)
$5.00 USD
+0.22 (4.60%)
Updated May 21, 2024 04:00 PM ET
After-Market: $5.00 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
HOWL 5.00 +0.22(4.60%)
Will HOWL be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for HOWL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HOWL
All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy
How Much Upside is Left in Werewolf Therapeutics, Inc. (HOWL)? Wall Street Analysts Think 92.37%
HOWL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Lags Revenue Estimates
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates
Strength Seen in Exelixis (EXEL): Can Its 5.6% Jump Turn into More Strength?
Other News for HOWL
Werewolf Therapeutics: Buy Rating Affirmed Amid Promising Clinical Advancements and Pipeline Potential
The Analyst Verdict: Werewolf Therapeutics In The Eyes Of 4 Experts
Buy Rating Affirmed for Werewolf Therapeutics Amid Promising Drug Candidate Developments
Buy Rating Affirmed for Werewolf Therapeutics Amid Promising Financials and Anticipated Clinical Updates
HOWL Stock Earnings: Werewolf Therapeutics Misses EPS, Misses Revenue for Q1 2024